NASDAQ
24.06.26 | 21:59
17,660 US-Dollar
+0,06 % +0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.06. | William Blair reiterates Cullinan Oncology stock rating on trial data | 3 | Investing.com | ||
| 10.06. | William Blair bestätigt "Outperform"-Rating für Cullinan Oncology nach Studiendaten | 1 | Investing.com Deutsch | ||
| 10.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases | 10 | GlobeNewswire (USA) | ||
| 08.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress | 3 | GlobeNewswire (USA) | ||
| 28.05. | Morocco and Finland Launch Business Council in Helsinki as Tazi Makes First European Outing as CGEM President | 2 | North Africa Post | ||
| 19.05. | Stifel reiterates Cullinan Oncology stock rating on trial data | 6 | Investing.com | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | 245 | GlobeNewswire (Europe) | Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan... ► Artikel lesen | |
| 18.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 15.05. | Tazi and Bachiri Elected to Lead CGEM with 91.5% of the Vote | 1 | North Africa Post | ||
| 07.05. | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | 2 | North Africa Post | ||
| 07.05. | Cullinan Therapeutics GAAP EPS of -$0.75 | 2 | Seeking Alpha | ||
| 07.05. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.03. | Gilead-Deal untermauert Potenzial: Clear Street bestätigt Kaufempfehlung für Cullinan Oncology | 18 | Investing.com Deutsch | ||
| 24.03. | Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation | 7 | Investing.com | ||
| 10.03. | Cullinan Therapeutics: Q4 Earnings Insights | 3 | Benzinga.com | ||
| 10.03. | Stifel raises Cullinan Oncology stock price target on autoimmune progress | 2 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,908 | -3,05 % | Clinuvel Pharmaceuticals Limited: CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study | EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its "totality of evidence" approachcentral photographic review and validated disease... ► Artikel lesen | |
| EDITAS MEDICINE | 2,470 | 0,00 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 0,920 | +1,10 % | Cardiol Therapeutics Inc: Cardiol Therapeutics to hold AGM virtually June 24 | ||
| CELLECTAR BIOSCIENCES | 2,490 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,097 | -0,72 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| CYTODYN | 0,180 | -10,89 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 7,300 | -1,88 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,190 | +1,42 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CEL-SCI | 0,840 | +2,44 % | CEL SCI CORP - 8-K, Current Report | ||
| CYTOKINETICS | 72,28 | +1,06 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,297 | -2,85 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,974 | +1,54 % | CytomX Therapeutics, Inc. - 8-K, Current Report | ||
| FAETH THERAPEUTICS | 24,600 | +0,24 % | H.C. Wainwright initiates Faeth Therapeutics stock coverage with buy rating | ||
| FATE THERAPEUTICS | 1,800 | -0,55 % | Globaler Biotech-Wettlauf und die Zukunft der Plattformstrategie - Warum Mesoblast auf den Pfaden von großen Konzernen wie Merck KGaA wandert | ||
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics |
Das Unternehmen CULLINAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 17,660 Euro und damit +0,06 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.